Neuromuscular Omnicentre (NeMO)

Centro Clinico Nemo

NeMO’s activity aims to improve the patient’s quality of life with effective interventions focused on minimizing the damage caused by ALS.

Centro Clinico Nemo

The NeuroMuscular Omnicentre (NeMO) is based at the Niguarda Ca’ Granda Hospital in Milan and is part of a network that consists of four clinical facilities distributed throughout Italy. We are a highly specialized center and devoted to take care of people affected with neuromuscular diseases, including ALS. We follow over 1000 neuromuscular patients each year. Using the expertise of our multidisciplinary team of specialists, we aim to cover the overall needs of ALS patients. We do this by offering comprehensive services in the areas of diagnosis, treatment, rehabilitation, nutrition and pulmonary care.

Contact
Location
Piazza dell'Ospedale Maggiore, 3, 20162 Milan, Metropolitan City of Milan, Italy

Our Specialists

Valeria Sansone

Associate Professor of Neurology and Director of Clinico Centro NeMO

I have had experience in neuromuscular disorders both from a clinical and […]

Valeria Sansone
Current trials
Recruiting
Phase iii

PHOENIX trial

Industry trial
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound 'AMX0035' for the treatment of ALS.
Read more
Recruiting
Phase iii

ADORE Trial

Industry trial
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
Read more
Recruiting
Phase iii

COURAGE-ALS Trial

Industry trial
In the COURAGE-ALS study, we are investigating the efficacy and safety of the drug ‘reldesemtiv’ for the treatment of ALS. This clinical trial is sponsored by Cytokinetics.
Read more
Active
Phase ii

APL2-ALS-206 Trial

Industry trial
In this phase 2 study, we are investigating the safety and efficacy of the drug pegcetacoplan for the treatment of ALS. This trial is sponsored by Apellis Pharmaceuticals.
Read more
Active
Phase ii

RT001 in Amyotrophic Lateral Sclerosis

Industry trial
In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.
Read more
Recruiting
Phase iii

TUDCA-ALS

Investigator initiated trial
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.
Read more